Cargando…
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Autores principales: | Greenberg, Richard N, Hurley, Maria Yadira, Dinh, Dinh V., Mraz, Serena, Vera, Javier Gomez, von Bredow, Dorothea, von Krempelhuber, Alfred, Roesch, Siegfried, Virgin, Garth, Arndtz-Wiedemann, Nathaly, Meyer, Thomas Peter, Schmidt, Darja, Nichols, Richard, Young, Philip, Chaplin, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640813/ https://www.ncbi.nlm.nih.gov/pubmed/26554703 http://dx.doi.org/10.1371/journal.pone.0142802 |
Ejemplares similares
-
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015) -
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
por: Greenberg, Richard N., et al.
Publicado: (2016) -
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
por: Zitzmann-Roth, Eva-Maria, et al.
Publicado: (2015) -
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009) -
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
por: Overton, Edgar Turner, et al.
Publicado: (2015)